NAYA (NAYA Biosciences Corp) Total Enterprise Value

Brandmark of NAYA Biosciences (NAYA)

NAYA Biosciences is actively developing innovative NK-therapy to combat solid tumors. This chart reflects a current share price of . The company's strategy relies on long-term intellectual property protection, establishing a foundation for future market dominance. Additionally, the business is based on partnerships with universities, leveraging laboratory resources to refine immune treatment methods.

NAYA NAYA Bio: Enterprise Value in the range 07/04/2022 - 10/28/2026
Manufactured products of NAYA Biosciences Inc

NAYA Biosciences' successes in developing anti-cancer therapies are directly reflected in the enterprise value dynamics, linking market valuation to financial stability. The sum of market capitalization and debt minus liquid assets determines the actual buyout cost of the business, which is critical for a biotech firm whose viability depends on external financing and partnerships with oncology centers in the absence of stable revenue.

Direct competitors

ONC - Enterprise Value|HALO (Halozyme Inc.) - Real Price to Acquire Entire Company|RVMD - Total Enterprise Value|AAPG: Enterprise Value|cgoncology.com (CGON) - Enterprise Value|Enterprise Value URGN|Real Price to Acquire Entire Company Bicara Therapeutics Inc|Enterprise Value PSNL|Enterprise Value ERAS (Erasca Oncology)|DCTH - Total Company Value|Business Value ymabs.com YMAB|AURA: Enterprise Value|CADL - Real Price to Acquire Entire Company|Enterprise Value ARAY|SLS (SELLAS Life Sciences Group) - Total Enterprise Value|ACTU - Total Company Value|Value Adjusted for Debt and Cash citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Enterprise Value|WHWK - Real Price to Acquire Entire Company|TScan - Real Price to Acquire Entire Company|CSBR: Enterprise Value|Total Company Value xbiotech.com XBIT|CEL-SCI (CVM) - Value Adjusted for Debt and Cash|Enterprise Value OSTX (OS Therapies Inc)|Total Enterprise Value RADX|Total Company Value Artiva Biotherapeutics, Inc. ARTV|Business Value adlainortye.com (ANL)|Enterprise Value VERU (Veru)|TPST - Enterprise Value|XLO (Xilio) - Real Price to Acquire Entire Company|RENB - Total Enterprise Value|MURA: Enterprise Value|Enterprise Value Kairos Pharma|OKUR - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash CytoMed|Enterprise Value Curis, Inc. (CRIS)|Total Company Value apollomicsinc.com (APLM)|Enterprise Value THAR|Advanced Biomed Inc. - Company Buyout Price|GNPX (Genprex) - Total Company Value|CLDI: Total Enterprise Value|Sunshine Biopharma, Inc. - Total Company Value|Xenetic Biosciences, Inc. (XBIO) - Company Buyout Price|Enterprise Value SLRX|Real Price to Acquire Entire Company purple-biotech.com|AONC (American Oncology Network) - Enterprise Value|Company Buyout Price BeiGene Ltd. (BGNE)|CKPT: Enterprise Value|elevationoncology.com - Total Enterprise Value|iCAD Corp (ICAD) - Total Company Value|IKNA - Business Value|NTBL (Notable Labs) - Enterprise Value|Viracta Therapeutics, Inc. (VIRX) - Real Price to Acquire Entire Company|Enterprise Value MOR (MorphoSys Corp)|Total Enterprise Value AAPGV